ARCHIVÉ - Lignes directrices pour la prévention et le contrôle des éclosions d’oreillons au Canada

 

Références

  1. Comité consultatif national de l’immunisation. Guide canadien d’immunisation. 7e éd. Ottawa : Agence de santé publique du Canada, 2006.
  2. Bell A, Fyfe M, Bigham M et coll. Outbreak of mumps among young adults – Vancouver, British Columbia. CCDR 1997;23(22):169-72.
  3. Bruneau A, Duchesne C. Outbreak of mumps, Montreal, October 1998 to March 1999 – with a particular focus on a school. CCDR 2000;26(8):69-71.
  4. Alberta Health and Wellness. Public health notifiable disease management guidelines (June 2005). URL: <http://www.health.gov.ab.ca/professionals/NotifiableDiseases.html>. Date d’accès : 23 novembre, 2007.
  5. Watson-Creed G, Saunders A, Scott J et coll. Two successive outbreaks of mumps in Nova Scotia among vaccinated adolescents and young adults. CMAJ 2006;175(5):483-88.
  6. Centre de l’immunisation et des maladies respiratoires infectieuses, Agence de la santé publique du Canada. Analyse de données près du Registre national des maladies à déclaration obligatoire. Ottawa : Agence de la santé publique du Canada, 2007.
  7. Leland DS. Parainfluenza and mumps viruses. Dans : Murray PR, Baron EJ, Jorgensen JH et al., éds. Manual of clinical microbiology. 9th ed. Washington DC: ASM Press, 2007.
  8. Robertson S. Mumps. Dans : Heymann DL, éd. Control of communicable diseases manual. 18th ed. Washington DC: American Public Health Association, 2004;376-79.
  9. American Academy of Pediatrics. Mumps. Dans : Pickering LK, éd. Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village: American Academy of Pediatrics, 2003:439-43.
  10. Zimmerman L, Reef S, Wharton M. Mumps. Dans : Wharton M, Hughes H, Reilly M, éds. Manual for the surveillance of vaccine-preventable diseases. 3rd ed. Atlanta: Centers for Disease Control and Prevention, 2002:7-1–7-12.
  11. Centers for Disease Control and Prevention. Mumps. Dans : Atkinson W, Hamborsky J, McIntyre L et al., éds. Epidemiology and prevention of vaccine-preventable diseases. 10th ed. Washington DC: Public Health Foundation, 2007;149-58.
  12. Seward et al Updated Recommendations for the Duration of Isolation Precautions for Persons with Mumps. MMWR 2008; 57:1103-5.
  13. Nova Scotia Health Promotion and Protection. Mumps outbreak case management and surveillance guidelines, May 2007. Version: May 14, 2007. Nova Scotia Health Promotion and Protection, 2007.
  14. Iowa Department of Public Health. Mumps. Revision 5/5/2006. Iowa Department of Public Health, 2006.
  15. Centers for Disease Control and Prevention. CDC health update – corrected: multi-state mumps outbreak. Health Alert Network, 26 April, 2006.
  16. Comité consultatif national de l’immunisation. Déclaration sur le vaccin contre les oreillons. RMTC 2007;33(DCC-8):1-10.
  17. Iowa Department of Public Health. Public health bulletin: Mass gathering policy – mumps. Iowa Department of Public Health, 18 April, 2006.
  18. Wharton M, Cochi SI, Hutcheson RH et coll. Mumps transmission in hospitals. Arch Intern Med 1990;150:47-9.
  19. Kaplan KM, Marder DC, Cochi SL et coll.Mumps in the workplace: further evidence of the changing epidemiology of a childhood vaccinepreventable disease. JAMA 1988;260:1434-38.
  20. Gupta RK, Best J, MacMahon E. Mumps and the UK epidemic 2005. BMJ 2005;330:1132-35.
  21. Davidkin I, Jokinen S, Paananen A et coll. Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella. J Infect Dis 2005;191:719-23.
  22. Centers for Disease Control and Prevention. Prevention and control of mumps in healthcare settings. URL: <http://www.cdc.gov/nip/diseases/mumps/control-hcw.htm>. Date d’accès : 31 octobre, 2007.
  23. Agence de la santé publique du Canada. La prévention et la lutte contre les infections professionnelles dans le domaine de la santé. RMTC 2002;28(S1):1-276.
  24. Agence de la santé publique du Canada. Guidelines for reporting a case of infectious tuberculosis on an aircraft (draft). Ottawa: Agence de la santé publique du Canada, 2007.
  25. Centers for Disease Control and Prevention. Exposure to mumps during air travel – United States, April 2006. MMWR 2006;55(14):401-02.
  26. World Health Organization. Tuberculosis and air travel: Guidelines for prevention and control. 2nd ed. World Health Organization, 2006.
  27. International Air Transport Association. Emergency response plan: A template for air carriers – public health emergency. International Air Transport Association, 2005.
  28. Quarantine Act, RSC 2005, c20, s82. Repeals RSC 1985, cQ-I.
  29. Rubin S, Mauldin J, Chumakov K et coll. Serological and phylogenetic evidence of monotypic immune responses to different mumps virus strains. Vaccine 2006;24:2662-68.
  30. Nöjd J, Tecle T, Samuelsson A et coll. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype. Vaccine 2001;19:1727-31.
  31. Örvell C, Alsheikhly AR, Kalantari M et coll. Characterization of genotype-specific epitopes of the HN protein of mumps virus. J Gen Virol 1997;78:3187-93.
  32. Jin L, Rima B, Brown D et al. Proposal for genetic characterisation of wild-type mumps strains: Preliminary standardisation of the nomenclature. Arch Virol 2005;150:1903-09.
  33. Plotkin S. Mumps vaccine. Dans : Plotkin S, Orenstein W & Offit P, eds. Vaccines. 4th ed. WB Saunders Company, 2003;441-60.
  34. Cohen C, White JM, Savage EJ et coll. Vaccine effectiveness estimated, 2004-2005 mumps outbreak, England. Emerg Infect Dis 2007;13(1):12-17.
  35. Gay N, Miller, Hesketh L et coll. Mumps surveillance in England and Wales supports introduction of two-dose vaccination schedule. Commun Dis Rep Rev 1997;7:R21-6.
  36. Harling R, White J, Ramsay M et coll. The effectiveness of the mumps component of the MMR vaccine: A case-control study. Vaccine 2005;23:4070-74.
  37. Wharton M, Cochi S, Hutcheson R et coll. A large outbreak of mumps in the postvaccine era. J Infect Dis 1988;158(6):1253-60.
  38. Vandermeulen C, Roelants M, Vermoere M et coll. Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Vaccine 2004;22:2713-16.
  39. Hersh B, Fine P, Kent W et coll. Mumps outbreak in a highly vaccinated population. J Pediatr 1991;119:187-93.
  40. Briss P, Fehrs L, Parker R et al. Sustained transmission of mumps in a highly vaccinated population: Assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis 1994;169:77-82.
  41. Peltola H, Heinonen O, Valle M et coll. The elimination of indigenous measles, mumps and rubella from Finland by a 12 year, twodose vaccination program. N Engl J Med 1994;331:1397-402.
  42. Pebody R, Gay N, Hesketh L et coll. Immunogenicity of second dose measles-mumpsrubella (MMR) vaccine and implications for serosurveillance. Vaccine 2002;20:1134-40.
  43. Davidkin I, Malle M, Julkunen I. Persistence of anti-mumps virus antibodies after a twodose MMR vaccination: A nine-year follow-up. Vaccine 1995;13(16):1617-22.
  44. Park DW, Nam MH, Kim JY et coll. Mumps outbreak in a highly vaccinated school population: Assessment of secondary vaccine failure using IgG avidity measurements. Vaccine 2007;25(24):4665-70.
  45. Health Protection Agency. MMR vaccination: Priorities for use in mumps outbreak. URL: <www.hpa.org.uk/infections/topics_az/mumps/images/MMRpriorities.pdf>. Date d’accès : 18 septembre, 2007.
  46. Santé Canada et l’Agence de la santé publique du Canada. Strategic risk communications framework and handbook. Thorne Butte: Decision Partners Inc. 2006.
  47. World Health Organization. Outbreak communication: Best practices for communicating with the public during an outbreak. World Health Organization, 2005.

Signaler un problème ou une erreur sur cette page
Veuillez sélectionner toutes les cases qui s'appliquent :

Merci de votre aide!

Vous ne recevrez pas de réponse. Pour toute question, contactez-nous.

Date de modification :